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INTRODUCTION
Cervical cancer is still a major health problem in
the developing countries like Indonesia. It was re-
ported that there is more than 2500 new cases
every year and the mortality ratio was 55%. De-
spite the success of cytologic techniques in diag-
Abstract
Objective: To know whether the expression of Fas Ligand has cor-
relation with incidene of metastasis of pelvic lymph node and
lymph-vascular stromal invasion (LVSI).
Methods: All patients diagnosed of cervical cancer stage IB or IIA
who underwent radical hysterectomy in Dr. Cipto Mangunkusumo
Central General Hospital from January 2008 until December 2009
were included in analytic cross sectional study. We tested expres-
sion of Fas Ligand in cervical cancer specimen by immunohysto-
chemistry with monoclonal antibody. The expression of Fas Ligand
was compared between the group of patients with a positive and
negative pelvic lymph node and between LVSI positive and negative.
The difference of expression in both group were statistically anal-
ized with Chi-square test and the correlation Spearman test.
Result: Ninety one patients underwent radical hysterectomy for two
years and 43 patients were included in these study. The expression
of Fas Ligand in 7 patients (16.3%) were negative and the others
were positive, with weak, moderate and strong expression were 4
(9.3%), 27 (62.8%), and 5 (11.6%) respectively. The expression of
Fas Ligand was significantly higher in the group of patients with
positive pelvic lymph node compared to the group of the patients
with negative pelvic lymph node (p=0.007) but there was no signifi-
cant difference between group of the patients with LVSI positive and
negative. With Spearman test, we found that the expression of Fas
Ligand had a strong correlation with pelvic lymph nodes metastasis
(coeff. correlation=0.519 and p=0.00) and have no correlation with
LVSI (coef. corellation=0.112 and p=0.474).
Conclusion: These finding suggested that expression of Fas Ligand
in cervical cancer patients has a strong correlation with the inci-
dence of pelvic lymph node metastasis and none with LVSI.
[Indones J Obstet Gynecol 2012; 36-4: 194-9]
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Abstrak
Tujuan: Ekspresi Fas Ligand memungkinkan sel-sel karsinoma me-
nginduksi apoptosis sel-sel imun sehingga dapat menghindarinya dan
melanjutkan pertumbuhan dan bermetastasis. Dengan demikian, ek-
spresi Fas Ligand memiliki korelasi dengan insiden metastase kelenjar
limfe pelvis dan limfovascular stromal invasion (LVSI).
Metode: Semua pasien yang terdiagnosa kanker servik stadium IB
atau IIA, yang menjalani histerektomi radikal di Rumah Sakit Umum
Pusat Dr. Cipto Mangunkusumo dari bulan Januari 2008 sampai De-
sember 2009 diikutsertakan dalam penelitian analitis cross sectional.
Kami menguji ekspresi Fas Ligand pada spesimen kanker serviks se-
cara imunohistokimia dengan antibodi monoklonal. Ekspresi Fas Li-
gand kemudian diperbandingkan antara pada kelompok pasien de-
ngan limfonodi pelvis positive dan negatif serta antara LVSI positif dan
negatif. Perbedaan ekspresi kedua kelompok dianalisa secara statistik
dengan Chi-square test dan analisa korelasi dengan Spearman test.
Hasil: Sembilan puluh satu pasien yang telah menjalani radikal his-
terektomi selama dua tahun dan 43 pasien diikutsertakan dalam
penelitian ini. Ekspresi Fas Ligand ditemukan negatif pada 7 pasien
(16,3%) dan positif lemah, moderat dan kuat pada 4 (9,3%), 27
(62,8%), dan 5 pasien (11,6%). Ekspresi Fas Ligand lebih tinggi secara
bermakna pada kelompok pasien dengan kelenjar limfe positif, namun
tidak ditemukan perbedaan pada kelompok pasien dengan LVSI posi-
tif dan negatif, dengan Spearman test, ekspresi Fas Ligand memiliki
korelasi kuat dengan metastasis limfonodi pelvis (koefisien kore-
lasi=0,519 dan p=0,00) dan tidak memiliki korelasi dengan LVSI (koe-
fisien korelasi=0,112 dan p=0,474).
Kesimpulan: Penemuan ini menunjukkan bahwa ekspresi Fas Ligand
pada kanker serviks memiliki korelasi kuat dengan metastase kelenjar
limfe pelvis dan tidak memiliki korelasi dengan LVSI.
[Maj Obstet Ginekol Indones 2012; 36-4: 194-9]
Kata kunci: fas ligand, imunohistokimia kanker servik, LVSI, metas-
tase limfonodi pelvis
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nosing precursor lesions and the early diagnosis of
invasive disease, the coverage of screening pro-
gram remains low.1,2
Among the prognostic factors, pelvic lymph
node metastasis and lymphovascular invasion
(LVSI) are considered the important factors that in-
fluence on management after radical hysterectomy
and affecting overall survival, recurrence rate and
disease free survival in early stage cervical cancer
after surgical treatment.3
Fas Ligand, one of the tumor necrosis factor fam-
ily proteins, is a type II membrane protein. It is
known that Fas L expressed on activated T lym-
phocytes or natural killer cells, which triggers
apoptosis on the cells that express Fas (CD95), one
of the tumor necrosis factor receptor families.
FasL-expressing tumors have been reported to
have a significantly worse prognosis. It is hypothe-
sized that these tumor cells can escape from im-
mune surveillance via a counter-attack on acti-
vated T cells, natural killer cells and TILs (Tumor
Infiltrating Leucocytes) that express Fas and cause
cancer cell able to continuing the growth and have
ability to invasion and metastasis.4,5
 Many investigation both in vitro and in vivo
have reported that Fas Ligand could induced apop-
tosis in lymphocyte cell at the microenvironment
of tumor cells and some studies found any relations
between increasing expression of Fas Ligand and
cancer metastasis and progression of tumor cells.5-7
There have also been reported at many type of
cancer like breast, melanoma and colorectal cancer,
expression of Fas Ligand (CD95L) have significant
correlation with lymph-node metastasis and lymph-
vascular stromal invasion.8,9
However, no research is available on the clinical
significance Fas Ligand in local lymph nodes and
Lymph-vascular stromal invasion (LVSI). To ex-
plore the relation between cervical cancer and re-
gional lymph node metastasis and LVSI, FasL pro-
tein expressions were detected using immunohis-
tochemistry method in this study.
METHODS
Specimens were obtained from 43 patients with
early stage cervical cancer (Stage IB1,IB2 and IIA)
who was admitted to the Department of Pathology
Dr. Cipto Mangunkusumo Central General Hospital
Jakarta, from January 2008 to December 2009. The
specimens were collected from patients that un-
derwent radical hysterectomy surgery. The speci-
mens were reviewed hystopatologically to deter-
mine the type of cancer and evaluation was done
to detect lymp-node metastasis and Lymp-vascular
stromal invasion (LVSI).
Immunohistochemistry
Specimens, fixed with 10% neutral formaldehyde
solution and embedded in paraffin, were cut into
4 μm thick sections. Briefly, endogenous peroxi-
dase was blocked by 3% hydrogen peroxide fol-
lowing deparaffinization. Novocastra Lyophililized
Mouse Monoclonal Antibody (production code
NCL-FAS-L) produce by Leica Biosystem Newcastle
was used as primary antibodies with 1:40 dilution
and incubated for 6 hours. Positive control was
taken from prostate specimens following its manu-
facturer’s instructions.
Evaluation of score
Intensity of staining was scored as 0: negative, 1:
light yellow, 2: brown-yellow and 3: brown. Eight
random highpower fields were observed under op-
tical microscope and 4 high-power fields were re-
corded as the percentage of positive cells. Extent
of staining was scored as 0: < 5%, 1: 5%-25%, 2:
26%-50%, 3: 51%-75% and 4: > 75%. The final
score was determined by multiplying the scores of
intensity and extent of staining, ranging 0-12.
Scores 9-12 were defined as strong staining (+++),
scores 4-8 as moderate staining (++), scores 1-3 as
weak staining (+), and 0 as negative staining (–).
Statistical analysis
Statistical analysis was performed using SPSS 15.0.
The data were analyzed using Spearman correla-
tion test and Chi-square test. P < 0.05 was consid-
ered statistically significant.
RESULT
Subject characteristic
In the recent study the average of age of the sample
was 48.35 year old, with the range of 33-63 year
old. The most frequent cases were at the group of
35-50 year old (55.8%), followed by the group of
over 50 year old (39.5%) and less frequent in the
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group of under 35 year old (4.7%). The mean of
parity was 4.09 with the range between 1-10 chil-
dren. Most patients admitted at Dr. Cipto Ma-
ngunkusumo Hospital were from low social econ-
omy group. Almost all patients had never had the
screening program (Pap Smear) (95.3%). The first
complain happened more or less 3.91 month be-
fore admission to the hospital. More than 70% pa-
tient first married before 20 years old. (Table 1)
Tabel 1. Demographic profile
Demographic
profile
n=43
n % Range
(min-max)
mean SD
(std deviaton)
age
<35
35-50
>50
 2
 4
17
 4.7
55.8
39.5
3 – 63 48.35 7.486
Parity
0
1-3
4-5
≥ 6
 0
18
15
10
0
41.8
34.9
23.3
1 – 10  4.09 1.986
Education
6 years
9 years
12 years
35
 6
 2
81.4
13.9
 4.7
Pap smear history
Ever
Never
 2
41
 4.7
95.3
Length of complain
1–3 months
> 3–6 months
> 6 months
21
18
 4
48.8
42.9
 8.3
1 – 8  3.91 1.887
Age of marriage
≤ 20
21-30
> 30
31
11
 1
72
25.6
 2.4
14 – 33 19.23 3.804
Clinicopathological characteristic
Clinicopathological feature showed at Table 2. The
histologic type of cancer found in this study were
squamous 24 cases (55.8%), adenocarcinoma and
adenosquamosa are 12 cases (27.9%) dan 7 cases
(16.3%) respectively. 25 cases (58.1%) are well
differentiated, poorly differentiation are 12 cases
(27.9%) and 6 cases are mild differentiation (14%).
There were 23 cases of stage 1B (53.5%), fol-
lowed by 17 cases (39.5%) of stage IIA and 3 cases
of stage IB2 (7%). The average amount of pelvic
lymph node was 17.02 with range of 4 to 38. The
most common found was 11-19 lymph nodes in 18
cases (41.9%), more than 20 lymph nodes in 16
cases (37.2%) and less than 10 lymph nodes in 9
cases (20.9%).
The size of tumor more than 4 cm only found at
6 cases (14%) and less than 4 cm were 37 cases
(86%). Long metastasis was found at follow up in
3 cases (6.97%).
The cutting margin of vagina and parametrium
that not free from tumor was found in 5 cases
(11.6%) dan 9 cases (20.9%) respectively while the
rest of cases have free margin of vagina in 38 cases
(88.4%) and parametrium 34 cases (79.1%).
Positive pelvic lymphnode metastasis was found
in 18 cases (41.9%) and 25 cases were negative
(58.1%). 27(62.8%) cases have positive LVSI and
16 cases (37.2%) have no LVSI.
Table 2. Clinicopathological Features
Clinicopathological
Characteristic
n = 43
n %
Stage
IB1
IB2
IIA
23
 3
17
53.5
 7  
39.5
Cell type
Squamous
Adenocarcinoma
Adenosquamous
24
12
 7
55.8
27.9
16.3
Differensiation
well
moderate
poor
 6
25
12
14  
58.1
27.9
Amount of lymphnodes
≤ 10
11–19
≥ 20
mean
range
 9
18
16
17.02
4-38
20.9
41.9
37.2
Size
≤ 4
More than 4 cm
37
 6
86
14
Distance metastasis
positive
negative
 3
40
 6.97
93.03
Vaginal margin
Negative
Posititive
38
 5
88.4
11.6
Parametrium
negative
positive
34
 9
79.1
20.9
Lymphnodes metastasis
Positive
Negative
18
322
41.9
51.2
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Fas Ligand Expression
FasL expression was observed in cervical cancer
cells with membranous and cytoplasmic staining.
This study showed the expression of Fas Ligand re-
garded as positive on 36 cases which 4 cases
(9.3%) weak expression, 27 cases (62.8%) moder-
ately expression and 5 cases (11.6%) have strong
expression. Negative Fas Ligand expression just
found at 7 cases (16.3%).
Bivariate analysis
This study showed that among the clinicopa-
thological factors, lymphnode metastasis have sig-
nificantly different of Fas Ligand expression be-
tween negative lymphnodes matastasis cases and
positive lymphnode metastasis cases (p=0.007).
The other factors, LVSI, differensiation, and cell
type were not showed not significant different of
Fas Ligand expression with p =0.108 (LVSI), grade
p=0.945, and cell type p=0.669. (Table 3)
Table 3. Chi-Square test between Fas Ligand expression
and clinicopathologic factors
Fas Ligand Expression (n=43)
p=0.05
negative weak moderate strong
Lymph nodes
Negative
Positive
7
0
4
0
13
14
1
4
0.007 (S) 
LVSI
Negative
Positive
5
2
0
4
 9
18
2
3
0.108 (NS)
Different
mild
moderate
poor
1
4
2
1
2
1
 4
 5
 8
0
4
1
0.945 (NS)
Cell type
Squamous
Adeno
Adeno skuamous
4
3
0
3
1
0
15
 6
 6
2
2
1
0.669 (NS)
Stage
IB1
IB2
IIA
5
0
2
2
0
2
14
 2
11
2
1
2
0.817 (NS)
Parametrium
Free
Not free
6
1
3
1
22
 5
3
2
0.701 (NS)
Vagina
Free
Not free
6
1
3
1
25
 2
4
1
0.670 (NS)
D. Negative control taken from normal cervical tissue
A. Positive control showed expression Fas Ligand expres-
sion on cytoplasma was taken from prostat tissue
B. Strong expression of Fas Ligand in cervical cancer cell
C. Negative/weak expression of Fas Ligand at cervical can-
cer tissue
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DISCUSSION
 There was 91 patients with early stage cervical
cancer (Stage IB1, IB2 and IIA) who underwent
radical hysterectomy at Dr. Cipto Mangunkusumo
Hospital, Jakarta for two years periode (2008-
2009), or 12 patients every month. Among these
cases just 43 cases met the criteria of this study.
Most patients came from low social economy
status, which was shown by the fact that more than
80% was not graduated from elementary school. It
can be understood because this hospital was aimed
mainly for low social economy class patients, since
the cost of treatment was paid by government
health assurance program. Almost all patients have
no history of screening test like Pap smear or VIA
test, and only 4.7% patients stated had ever done
screening test. This is appropriate with the fact that
coverage of the screening program is still low (be-
low 5%) especially at the group of low social econ-
omy class.1
In this study the mean age of the patients 48.35
with the youngest patient was 33 years old and the
oldest patient was 63 years old. The most frequent
cases are at the group 35-50 years old. This finding
is appropriate with former study by Azis et al,
stated that cervical cancer occurs more frequent in
the group 35-50 years old.
More than 70% patient had married when they
were less than 20 years old year old (probably the
first year intercourse). This finding is not surpris-
ing because the patients came from middle low so-
cial economy and have low education. In this group
the marriage tend to happen at the very young age.
The mean parity of patiens in this study was 4.09
children this fact supported the assumption that
multiparity is one of risk factor in cervical cancer.
Cancer cells expressing high level of FasL are
able to attack tumor-infiltrating immune cells ex-
pressing high Fas levels by promoting apoptosis of
immune cells, thus allowing cancer cells to escape
immune attack. In our study, the Fas expression
level was significantly higher in positive lymph
nodes patient than in negative lymph nodes, sug-
gesting that cancer cells with a high Fas Ligand ex-
pression level may be more susceptible to self-
apoptosis, thereby promoting lymph node metas-
tasis.
Many malignant tumors have been reported to
express FasL. Hahne et al reported that melanoma
cells expressing FasL grew more rapidly in wild-
type mice than in Fasmutant lpr mice. From their
experiment, it was expected that FasL expression
in tumor cells would affect tumor progression and
the prognosis of patients. In fact, FasL expression
had a significant association with lymph node me-
tastasis in breast cancer, gastric cancer, and col-
orectal cancer.
Our study showed Fas Ligand expression re-
garded as moderate and strong were found in 32
patients (74.4%) and negative or weak expression
were found in 11 patients (25.6%). Munakata et al
found similar result, in which 74.4% cervical car-
cinoma express Fas Ligand.9 Ibrahim et al studied
Fas Ligand expression in squamous cervical carci-
noma and intraepithelial neoplasia stated 64%
cases had positive Fas Ligand expression, while
Kase et al observed Fas Ligand expression in cer-
vical adenocarcinoma found 62.5% primary tu-
mour had positive Fas Ligand expression.3,5,6 It
seems that expression of Fas Ligand in this study
was consistent with other studies.
This recent study found expression Fas Ligand
was significantly higher in patients with positive
lymph nodes metastasis compared to patients with
negative lymph nodes (p=0.007) but not signifi-
cantly different in LVSI positive or negative
(p=0.108). Kase et al found Fas Ligand expression
was significantly higher in both positive lymph
nodes metastasis and positive LVSI.3 These differ-
ent finding was probably caused by different study
sample that did not include the patients who re-
ceived neoadjuvant chemotherapy before surgery.
For the other clinicopathological factors (stage,
cell type, grade, parametrium and vaginal involve-
ment), expression of Fas Ligand was not signifi-
cantly different. Kase et al stated that all lymph
nodes metastasis had strong expression of Fas Li-
gand, thus indicated that Fas Ligand have impor-
tant role for evasion of tumor from immune sur-
veillance because only cell expressed Fas Ligand
can successfully achieve the lymph nodes.3 Mu-
nakata et al found that high expression of Fas Li-
gand in cervical cancer cell ascociated with poor
prognosis, while Ibrahim et al stated only cancer
cell that have Fas Ligand expression can make
apoptosis of jurkat and T cell.8 These finding sup-
port the theory of Fas Ligand’s important role via
counter-attack mechanism on progressivity and
behavior of cancer cell.
Metaanalysis study stated that limph nodes me-
tastasis was a constant prognostic factor in 22 from
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25 article (88%), while LVSI has significant prog-
nosis factors just in 12% article, this fact supports
the assumption that Fas Ligand expression has sig-
nificant ascociation with prognosis of cervical can-
cer patients as had been investigated by Munakata
et al.8
CONCLUSION
Expression of Fas Ligand was significantly higher
in the group of patients with positive lymph nodes
metastasis cervical cancer compare with negative
patients and not significantly different between pa-
tients with positive LVSI and negative LVSI. In-
creasing of Fas Ligand have significant correlation
with lymph nodes metastasis and have not signifi-
cant association with LVSI.
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